Research Capsules

February 2009
Pharmaceutical Representative;Feb2009, Vol. 39 Issue 2, p11
The article offers news briefs related to the clinical drug trials in the U.S. The Veterans Affairs Diabetes Trial reveals that tight control of glucose levels may not prevent cardiovascular events in type 2 diabetes. Combined data from two Phase III double-blind trials show that Access Pharmaceuticals Inc.'s pexiganan may be a good alternative to oral antibiotics for mild diabetic foot infection. A double-blind study shows that telcagepant may offer relief similar to that of Zomig.


Related Articles

  • Esculentin-2CHa-Related Peptides Modulate Islet Cell Function and Improve Glucose Tolerance in Mice with Diet-Induced Obesity and Insulin Resistance. Ojo, Opeolu O.; Srinivasan, Dinesh K.; Owolabi, Bosede O.; Vasu, Srividya; Conlon, J. Michael; Flatt, Peter R.; Abdel-Wahab, Yasser H. A. // PLoS ONE;29/10/2015, Vol. 10 Issue 10, p1 

    The frog skin host-defense peptide esculentin-2CHa (GFSSIFRGVA10KFASKGLGK D20LAKLGVDLVA30CKISKQC) displays antimicrobial, antitumor, and immunomodulatory properties. This study investigated the antidiabetic actions of the peptide and selected analogues. Esculentin-2CHa stimulated insulin...

  • Canagliflozin. Cada, Dennis J.; Ingram, Kyle T.; Levien, Terri L.; Baker, Danial E. // Hospital Pharmacy;Nov2013, Vol. 48 Issue 10, p855 

    The article focuses on clinical pharmacology, pharmacokinetics and efficacy of drug Canagliflozin. It mentions that Canagliflozin lowers blood glucose in a dose dependent manner by lowering the renal threshold for glucose and increasing the excretion of glucose by inhibition of renal sodium...

  • A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. Goldberg, Ronald B.; Kendall, David M.; Deeg, Mark A.; Buse, John B.; Zagar, Anthony J.; Pinaire, Jane A.; Tan, Meng H.; Khan, Mehmood A.; Perez, Alfonso T.; Jacober, Scott J. // Diabetes Care;Jul2005, Vol. 28 Issue 7, p1547 

    OBJECTIVE -- Published reports suggest that pioglitazone and rosiglitazone have different effects on lipids in patients with type 2 diabetes. However, these previous studies were either retrospective chart reviews or clinical trials not rigorously controlled for concomitant glucose- and...

  • SGLT2 inhibition--a novel strategy for diabetes treatment. Chao, Edward C.; Henry, Robert R. // Nature Reviews Drug Discovery;Jul2010, Vol. 9 Issue 7, p551 

    Inhibiting sodium-glucose co-transporters (SGLTs), which have a key role in the reabsorption of glucose in the kidney, has been proposed as a novel therapeutic strategy for diabetes. Genetic mutations in the kidney-specific SGLT2 isoform that result in benign renal glycosuria, as well as...

  • Achieving HbA1c targets and reducing risk of complications. Devendra, Devasenan // GP: General Practitioner;11/14/2008, p34 

    The article reviews the evidence for good glycemic control in type-2 diabetes. It discusses studies that have demonstrated the potential benefits of improving glycemic control to achieve HbA1c targets in patients with type-2 diabetes. It notes that the United Kingdom Prospective Diabetes Study...

  • Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes. Cook, Michael N.; Girman, Cynthia J.; Stein, Peter P.; Alexander, Charles M.; Holman, Rury R. // Diabetes Care;May2005, Vol. 28 Issue 5, p995 

    OBJECTIVE -- To describe the course and predictors of glycemic control among patients with type 2 diabetes after sulfonylureas (SUs) are added to metformin (MF). RESEARCH DESIGN AND METHODS -- Patients (n = 2,220) treated with MF monotherapy for >90 days before initiating MF plus SU combination...

  • Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes. Neumiller, Joshua J. // Clinical Diabetes;Fall2014, Vol. 32 Issue 4, p170 

    The article discusses the effficacy and safety of saxaglipitin as an add-on treatment for patients with type 2 diabetes who have inadequate glycemic control despite receiving one or more of a variety of commonly used antihyperglycemic agents. Effects of combining saxaglipitin with other...

  • Therapy type affects weight increase.  // Diabetes Digest;2012, Vol. 11 Issue 2, p86 

    The article discusses a study to evaluate weight change in people with type 2 diabetes (T2D) and the impact of alternative anti-hyperglycemic drugs, which revealed that there was a continual increase in body weight in people with T2D.

  • Diabetes roundup. Greener, Mark // Independent Nurse;10/17/2016, p12 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics